• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of genetics >Induced pluripotent stem cells for retinal degenerative diseases: a new perspective on the challenges
【24h】

Induced pluripotent stem cells for retinal degenerative diseases: a new perspective on the challenges

机译：诱导多能干细胞治疗视网膜退行性疾病：挑战的新视角

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Retinal degenerative diseases, including age-related macular degeneration and retinitis pigmentosa, are the prodominant causes of human blindness in the world; however, these diseases are difficult to treat. Currently, knowledge on the mechanisms of these diseases is still very limited and no radical drugs are available. Induced pluripotent stem (iPS) cells are an innovative technology that turns somatic cells into embryonic stem (ES)-like cells with pluripotent potential via the exogenous expression of several key genes. It can be used as an unlimited source for cell differentiation or tissue engineering, either of which is a promising therapy for human degenerative diseases. Induced pluripotent cells are both an unlimited source for retinal regeneration and an expectant tool for pharmaprojects and developmental or disease modelling. In this review, we try to summarize the advancement of iPS-based technologies and the potential utility for retinal degenerative diseases. We also discuss the challenges of using this technology in the retinology field.
机译：视网膜变性疾病，包括与年龄有关的黄斑变性和色素性视网膜炎，是世界上人类失明的主要原因。但是，这些疾病很难治疗。当前，关于这些疾病的机制的知识仍然非常有限，并且尚无自由基药物。诱导多能干（iPS）细胞是一项创新技术，可通过几种关键基因的外源表达将体细胞转变为具有多潜能的胚胎干（ES）样细胞。它可以用作细胞分化或组织工程的无限来源，这两种方法都可以用于人类退行性疾病。诱导的多能细胞既是视网膜再生的无限来源，又是药学项目和发育或疾病建模的预期工具。在这篇综述中，我们试图总结基于iPS的技术的进步以及视网膜退行性疾病的潜在效用。我们还将讨论在视网膜病领域使用该技术的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号